Overview

A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer

Status:
Not yet recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

A multi-center, open, randomized controlled, phase II clinical study to evaluate the efficiency and safety of chemotherapy and immunotherapy combined with locol radiotharepy in treatment of patients with oligometastatic esophageal carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Zhejiang Cancer Hospital

Collaborators:

Huizhou Municipal Central Hospital
Jinhua Municipal Central Hospital Medical Group
Lishui Municipal Central Hospital
People's Hospital of Quzhou
Sun Yet-sen Cancer Center
The Affiliated People's hospital of Ningbo Univercity
The First Affiliated Hospital of Wenzhou Medical Univercity
Zhejiang Provincial People's Hospital